Results 201 to 210 of about 475,202 (310)

Lupus Disseminatus [PDF]

Proceedings of the Royal Society of Medicine, 1927
openaire   +2 more sources

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

2104 Lupus autoantibodies associated with cell cycle gene expression in peripheral blood of SLE patients

Lupus Science and Medicine, 2022
Mary K Crow, Kyriakos A Kirou, Mikhail Olferiev, Dina Greenman, Jeffrey Zhang-Sun, David Fernandez   +5 more
doaj   +1 more source

Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data. [PDF]

Lupus Sci Med
Peterknecht E, Branco M, Reynolds JA.
europepmc   +1 more source

Lupus Vulgaris [PDF]

BMJ, 1937
openaire   +2 more sources

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Taurine supplementation and systemic lupus erythematosus in preclinical studies: a systematic review of clinical outcomes and underlying mechanisms. [PDF]

Amino Acids
Malek Mahdavi A, Javadivala Z, Orooji N.
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

Spondyloarthritis Preceding and Following Inflammatory Bowel Disease Diagnosis and Risk Factors: A Temporal Trends Analysis in a Population‐Based Cohort

Arthritis &Rheumatology, EarlyView.
Objective Spondyloarthritides (SpA) and inflammatory bowel disease (IBD) are immune‐mediated diseases with overlap in clinical and immunologic features. However, temporal correlation of SpA and IBD in individual patients and risk factors are not well characterized.
Manasi Agrawal, Christian N. Sørensen, Gry J. Poulsen, Bahar Moghaddam, Percio S. Gulko, Jean‐Frederic Colombel, Tine Jess   +6 more
wiley   +1 more source

Frequency and associated factors of herpes zoster infection in SLE patients from Latin America: data from the GLADEL 2.0 cohort. [PDF]

Lupus Sci Med
Nieto R, Hernández L, Scolnik M, Maurelli L, Gobbi C, Saurit V, Garcia L, Kisluk B, Bertolaccini MC, Serna Góngora M, Gómez GN, Pisoni C, Ralle AC, Pirruccio P, de Souza Barbosa V, Gasparin A, Duarte A, Alves Alvino LC, Borba EF, Bonfá E, Reis-Neto ETD, Bondi Peralta A, Massardo L, Aroca Martínez G, Iglesias Gamarra A, Cañas CA, Quintana López G, Frederick Silvery L, Martinez JM, Sánchez-Briones R, Pérez Cristóbal M, Martín-Nares E, Silveira LH, García De La Torre I, Ramírez Sánchez JC, Esquivel-Valerio JA, Losanto J, Vazquez MA, Linares MA, Ugarte-Gil MF, Calvo-Quiroz A, Polanco T, Pizzarossa C, Silveira G, Pons-Estel BA, Alarcon GS, Pons-Estel G.   +46 more
europepmc   +1 more source